Advertisement

Chemotherapy of Prostate Cancer: The National Prostatic Cancer Project Experience

  • J. D. Schmidt
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 53)

Abstract

Since 1972 the Treatment Subgroup of the National Prostatic Cancer Project has accessioned 1748 patients with various stages of prostatic cancer to 13 different treatment protocols. Seven of these protocols have been closed and the results in the initial studies have been published. Six protocols are active and continue to accrue patients. Principal investigators have a prominent role in protocol design as well as in the evaluation and publication of data emanating from these protocols. Active agents identified to date include cyclophosphamide, 5-fluorouracil, methyl-CCNU, imidazole-carboxamide, estramustine phosphate and streptozotocin. Agents chosen for their presumed activity, but currently under investigation, include methotrexate and cis-platinum.

Keywords

Divided Dose Estramustine Phosphate Clinical Trial Program ATIC Cancer Treatment Subgroup 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    W.W. Scott, R.P. Gibbons, D.E. Johnson, G.R. Prout, Jr., J.D. Schmidt, J. Saroff, and G.P. Murphy, The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate, J. Urol. 116:211 (1976).PubMedGoogle Scholar
  2. 2.
    G.P. Murphy, R.P. Gibbons, D.E. Johnson, S.A. Loening, G.R. Prout, J.D. Schmidt, D.S. Bross, T.M. Chu, J.F. Gaeta, J. Saroff, and W.W. Scott, A comparison of estramustine phosphate and streptozotocin in patients with advanced prostatic carcinoma who have had extensive irradiation, J. Urol 118:288 (1977).PubMedGoogle Scholar
  3. 3.
    J.D. Schmidt, W.W. Scott, R.P. Gibbons, D.E. Johnson, G.R. Prout, Jr., S.A. Loening, M.S. Soloway, T.M. Chu, J.F. Gaeta, N.H. Slack, J. Saroff, and G.P. Murphy, Comparison of procarbazine, imidazole-carboxamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate, J. Urol. 121:185 (1979).PubMedGoogle Scholar
  4. 4.
    S.A. Loening, J.B. deKernion, R.P. Gibbons, D.E. Johnson, J.E. Pontes, G.R. Prout, Jr., J.D. Schmidt, W.W. Scott, M.S. Soloway, N.H. Slack, and G.P. Murphy, A comparison of hydroxyurea, methyl-CCNU and cyclophosphamide in patients with advanced carcinoma of the prostate, J. Urol. In Press.Google Scholar
  5. 5.
    G.P. Murphy, R.P. Gibbons, D.E. Johnson, G.R. Prout, J.D. Schmidt, M.S. Soloway, S.A. Loening, T.M Chu, J.F. Gaeta, J. Saroff, Z. Wajsman, N. Slack, and W.W. Scott, The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation, J. Urol, 121:763 (1979).PubMedGoogle Scholar
  6. 6.
    M.S. Soloway, J.B. deKernion, R.P. Gibbons, D.E. Johnson, S. Loening, J.E. Pontes, G.R. Prout, J.D. Schmidt, W.W. Scott, N.H. Slack, and G.P. Murphy, Comparison of Estracyt and vincristine alone or in combination for patients with advanced hormone-refractory, previously irradiated carcinoma of the prostate, J. Urol. In Press.Google Scholar
  7. 7.
    J.D. Schmidt, W.W. Scott, R. Gibbons, D.E. Johnson, G.R. Prout, Jr., S. Loening. M. Soloway, J. deKernion, J.E. Pontes, N.H. Slack, and G.P. Murphy, Chemotherapy programs of the National Prostatic Cancer project, Cancer 45:1937 (1980).PubMedGoogle Scholar
  8. 8.
    R.P. Gibbons and Investigators, National Prostatic Cancer Project Cooperative Clinical Trials: Cooperative clinical trial of single and combined agent protocols: Adjuvant protocols, Urology (Suppl.), 17:48 (1981).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • J. D. Schmidt
    • 1
  1. 1.University of California Medical CenterSan DiegoUSA

Personalised recommendations